Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
A7E2Y1

UPID:
MYH7B_HUMAN

ALTERNATIVE NAMES:
Antigen MLAA-21; Myosin cardiac muscle beta chain; Myosin heavy chain 7B, cardiac muscle beta isoform; Slow A MYH14

ALTERNATIVE UPACC:
A7E2Y1; Q5JVW7; Q6NT44; Q6NT57; Q6WG75; Q96I57; Q9NWE2; Q9P216

BACKGROUND:
The protein Myosin-7B, also referred to as Slow A MYH14, is integral to the process of muscle contraction. Its various names, including Antigen MLAA-21 and Myosin cardiac muscle beta chain, reflect its significant role in cardiac muscle physiology and its potential as a biomarker in cardiovascular research.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Myosin-7B holds the promise of unveiling new therapeutic avenues. Given its pivotal role in cardiac muscle contraction, research into Myosin-7B could pave the way for groundbreaking therapies in heart disease, emphasizing the protein's therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.